Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PharmB > Non-Insulin Drugs to Treat Diabetes > Flashcards

Non-Insulin Drugs to Treat Diabetes Flashcards

1
Q

Sulfonylureas are used in the treatment of diabetes?
• 1st generation?
• 2nd Generation?

A

Sulfonylureas:

  • *1st Chlorpropamide, tolbutamide**
  • *2nd Glyburide, glipizide, glimepiride – the “G-ides”**
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Chorapropamide
MOA
T1DM/T2DM?
Metabolism

A

Sulfonylureas: 1st Chlorpropamide, tolbutamide; 2nd Glyburide, glipizide, glimepiride – the “G-ides”

**TD2M tx only…Requires Islet cell function**

MOA:
These block the ATP-dependent potassium channel in ß-cells leading to depolarization, opening of Ca2+ channels, and release of insulin vesicles.

Metabolism:
These are extensively protein bound, metabolized by the liver and excreted by the kidney

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Chlorapropamide
Side Effects
Contraindications
Administration

A

Sulfonylureas: 1st Chlorpropamide, tolbutamide; 2nd Glyburide, glipizide, glimepiride – the “G-ides”

**TD2M tx only…Requires Islet cell function**

Side Effects:
Hypoglycemia, Renal failure, first generations (chloropropamide, and tolbutamide) have disulfram-like effects.

Contraindications:
NSAIDs cause increased likelihood of hypoglycemic events

Administration:
Oral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Tolbutamide
MOA
T1DM/T2DM?
Metabolism

A

Sulfonylureas: 1st Chlorpropamide, tolbutamide; 2nd Glyburide, glipizide, glimepiride – the “G-ides”

**TD2M tx only…Requires Islet cell function**
MOA:

These block the ATP-dependent potassium channel in ß-cells leading to depolarization, opening of Ca2+ channels, and release of insulin vesicles.

Metabolism:
These are extensively protein bound, metabolized by the liver and excreted by the kidney

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Tolbutamide
Side Effects
Contraindications
Administration

A

Sulfonylureas: 1st Chlorpropamide, tolbutamide; 2nd Glyburide, glipizide, glimepiride – the “G-ides”

**TD2M tx only…Requires Islet cell function**

Side Effects:
Hypoglycemia, Renal failure, first generations (chloropropamide, and tolbutamide) have disulfram-like effects.

Contraindications:
NSAIDs cause increased likelihood of hypoglycemic events

Administration:
Oral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Glyburide
MOA
T1DM/T2DM?
Metabolism

A

Sulfonylureas: 1st Chlorpropamide, tolbutamide; 2nd Glyburide, glipizide, glimepiride – the “G-ides”

**TD2M tx only…Requires Islet cell function**
MOA:

These block the ATP-dependent potassium channel in ß-cells leading to depolarization, opening of Ca2+ channels, and release of insulin vesicles.

Metabolism:
These are extensively protein bound, metabolized by the liver and excreted by the kidney

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Glyburide
Side Effects
Contraindications
Administration

A

Sulfonylureas: 1st Chlorpropamide, tolbutamide; 2nd Glyburide, glipizide, glimepiride – the “G-ides”

**TD2M tx only…Requires Islet cell function**

Side Effects:
Hypoglycemia, Renal failure, first generations (chloropropamide, and tolbutamide) have disulfram-like effects.

Contraindications:
NSAIDs cause increased likelihood of hypoglycemic events

Administration:
Oral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Glipizide
MOA
T1DM/T2DM?
Metabolism

A

Sulfonylureas: 1st Chlorpropamide, tolbutamide; 2nd Glyburide, glipizide, glimepiride – the “G-ides”

**TD2M tx only…Requires Islet cell function**
MOA:

These block the ATP-dependent potassium channel in ß-cells leading to depolarization, opening of Ca2+ channels, and release of insulin vesicles.

Metabolism:
These are extensively protein bound, metabolized by the liver and excreted by the kidney

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Glipizide
Side Effects
Contraindications
Administration

A

Sulfonylureas: 1st Chlorpropamide, tolbutamide; 2nd Glyburide, glipizide, glimepiride – the “G-ides”

**TD2M tx only…Requires Islet cell function**

Side Effects:
Hypoglycemia, Renal failure, first generations (chloropropamide, and tolbutamide) have disulfram-like effects.

Contraindications:
NSAIDs cause increased likelihood of hypoglycemic events

Administration:
Oral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Glimpiride
MOA
T1DM/T2DM?
Metabolism

A

Sulfonylureas: 1st Chlorpropamide, tolbutamide; 2nd Glyburide, glipizide, glimepiride – the “G-ides”

**TD2M tx only…Requires Islet cell function**
MOA:

These block the ATP-dependent potassium channel in ß-cells leading to depolarization, opening of Ca2+ channels, and release of insulin vesicles.

Metabolism:
These are extensively protein bound, metabolized by the liver and excreted by the kidney

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Glimepiride
Side Effects
Contraindications
Administration

A

Sulfonylureas: 1st Chlorpropamide, tolbutamide; 2nd Glyburide, glipizide, glimepiride – the “G-ides”

**TD2M tx only…Requires Islet cell function**

Side Effects:
Hypoglycemia, Renal failure, first generations (chloropropamide, and tolbutamide) have disulfram-like effects.

Contraindications:
NSAIDs cause increased likelihood of hypoglycemic events

Administration:
Oral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What Meglintinides are used in the treatment of Diabetes?

A

Meglitinides: repaglinide, nateglinide – the “glinides”

*Similar function to sulfonureas, but different structure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Repaglinide
MOA
Metabolism
T1DM/T2DM?

A
  • *Meglitinides** repaglinide, nateglinide – the “glinides”
  • **TD2M tx only…Requires Islet cell function***

MOA:
These block the ATP-dependent potassium channel in ß-cells leading to depolarization, opening of Ca2+ channels, and release of insulin vesicles.
***Structurally unrelated to sulfonureas***

Metabolism:
Taken before meals; metabolized by the liver; Short half-life

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Repgalinide
Side Effects
Contraindications
Administration

A

Meglitinides repaglinide, nateglinide – the “glinides”

Side Effects:
Hypoglycemia – more likely to see this with meglitinides than with sulfonureas

Containdications:
None mentioned

Administration:
Oral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Nateglinide
MOA
Metabolism
T1DM/T2DM?

A

Meglitinides repaglinide, nateglinide – the “glinides”
**TD2M tx only…Requires Islet cell function**
MOA:

These block the ATP-dependent potassium channel in ß-cells leading to depolarization, opening of Ca2+ channels, and release of insulin vesicles.
***Structurally unrelated to sulfonureas***

Metabolism:
Taken before meals; metabolized by the liver; Short half-life

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Nateglinide
Side Effects
Contraindications

A

Meglitinides repaglinide, nateglinide – the “glinides”

Side Effects:
Hypoglycemia – more likely to see this with meglitinides than with sulfonureas

Containdications:
None mentioned

Administration:
Oral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What biguanides are used in the treatment of DM?

A

Biguanides: Phenformin (no longer used), Metformin – the “formins”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Metformin
MOA
Metabolism

A

Biguanides: Phenformin (no longer used), Metformin – the “formins”
****First-line therapy in T2DM*****CAN be used in T1DM
MOA:
These work by increasing AMP kinase activity that is typically activated in times of low ATP so it phosphorylates enzymes used in glycolysis an others that leads to lowering of blood glucose. (decreases gluconeogenesis, increases glycolysis, and increases peripheral glucose uptake.

Metabolism:
not mentioned

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Metformin
Side Effects
Contraindications
Administration

A
  • *Biguanides:** Phenformin (no longer used), Metformin – the “formins”
  • ****First-line therapy in T2DM*****CAN be used in T1DM*

Side Effects:
LACTIC ACIDOSIS, GI upset

Lactic acidosis makes sense because metformin increases glycolysis and may overwhelm the ox-phos pathway

Containdications:
Renal Insufficiency – because of the risk of lactic acidosis

Administration:

Oral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

That thiazolidindiones are used in the treatment of DM?
• how do they work?

A

Thiazolidindiones: troglitazone, rosiglitazone, pioglitazone, rosiglitazone + metformin – the “azones”

MOA:
Binds to Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) – a nuclear transcription regulator. This leads to increased insulin sensitivity peripherally. Ultimately this leads to increased glucose transport into muscles and adipose tissue.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Troglitazone
MOA
Metabolism

A

Thiazolidindiones: troglitazone, rosiglitazone, pioglitazone, rosiglitazone + metformin – the “azones”

MOA:
Binds to Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) – a nuclear transcription regulator. This leads to increased insulin sensitivity peripherally. Ultimately this leads to increased glucose transport into muscles and adipose tissue.

Metabolism:
Absorbed from GI tract, little metabolism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Troglitazone
Side Effects
Contraindications
Administration

A

Thiazolidindiones: troglitazone, rosiglitazone, pioglitazone, rosiglitazone + metformin – the “azones”

Side Effects:
Increased risk of fractures, Hepatotoxicity, weight gain, edema

Containdications:
safe even with renal impairment

Administration:

Oral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Rosaglitazone
MOA
Metabolism

A

Thiazolidindiones: troglitazone, rosiglitazone, pioglitazone, rosiglitazone + metformin – the “azones”

MOA:
Binds to Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) – a nuclear transcription regulator. This leads to increased insulin sensitivity peripherally. Ultimately this leads to increased glucose transport into muscles and adipose tissue.

Metabolism:
Absorbed from GI tract, little metabolism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Rosaglitazone
Side Effects
Contraindications
Administration

A

Thiazolidindiones: troglitazone, rosiglitazone, pioglitazone, rosiglitazone + metformin – the “azones”

Side Effects:

Increased risk of fractures, Hepatotoxicity, weight gain, edema

Containdications:
safe even with renal impairment

Administration:

Oral

25
Q

What alpha glucosidase inhibitors are used in the treatment of DM?

A

Alpha-glucosidase inhibitors: acarbose, miglitol

26
Q

Acarbose
MOA
Metabolism

A

Alpha-glucosidase inhibitors: acarbose, miglitol

MOA:
Inhibition of intestinal brush-border alpha-glucosidases – remember glucose must be in its monomeric form to be absorbed so this allows it to move through the GI tract – this decreases the rise in post-prandial glucose

Metabolism:
not mentioned

27
Q

Acarbose
Side Effects
Contraindications
Administration

A

Alpha-glucosidase inhibitors: acarbose, miglitol

Side Effects:
GI disturbances (flatulence) are common because more sugar makes it to your colonic flora

Containdications:
none mentioned

Administration:

Oral – typically used as a combination drug

28
Q

Miglitol
MOA
Metabolism

A

Alpha-glucosidase inhibitors: acarbose, miglitol

MOA:
Inhibition of intestinal brush-border alpha-glucosidases – remember glucose must be in its monomeric form to be absorbed so this allows it to move through the GI tract – this decreases the rise in post-prandial glucose

Metabolism:
not mentioned

29
Q

Miglitol
Side Effects
Contraindications
Administration

A

Alpha-glucosidase inhibitors: acarbose, miglitol

Side Effects:
GI disturbances (flatulence) are common because more sugar makes it to your colonic flora

Containdications:
none mentioned

Administration:

Oral – typically used as a combination drug

30
Q

What GLP-1 analogs are used to treat DM?

A

Incretins – GLP-1 agonists: Exentatide, Ilraglutide – the “tides”

31
Q

Exentatide
MOA
T1DM or T2DM?

A

Incretins – GLP-1 agonists: Exentatide, Ilraglutide – the “tides”
***These drugs will only be useful in T2DM***

MOA:
GLP-1 is secreted by the L-cells in the distal ileum and colon and increases glucose dependent insulin secretion, decreases glucagon release, decreases gastric emptying, and increases satiety – all of these actions decrease postprandial glucose – THIS DRUG ACTS ON THE GLP-1 RECEPTOR

32
Q

Extentatide

A

Incretins – GLP-1 agonists: Exentatide, Ilraglutide – the “tides”

Side Effects:

Nausea, vomiting, pancreatitis, weight loss (both of these make sense based on the MOA, you’re activating pancreatic cells)

33
Q

Liraglutide
MOA
T1DM or T2DM?
Administration

A

Incretins – GLP-1 agonists: Exentatide, Ilraglutide – the “tides”
***These drugs will only be useful in T2DM***

MOA:
GLP-1 is secreted by the L-cells in the distal ileum and colon and increases glucose dependent insulin secretion, decreases glucagon release, decreases gastric emptying, and increases satiety – all of these actions decrease postprandial glucose – THIS DRUG ACTS ON THE GLP-1 RECEPTOR

**LIRAGLUTIDE must be injected SC

34
Q

Liraglutide
Side effects

A

Incretins – GLP-1 agonists: Exentatide, Ilraglutide – the “tides”

Side Effects:

Nausea, vomiting, pancreatitis, weight loss (both of these make sense based on the MOA, you’re activating pancreatic cells)

35
Q

What DPP-4 inhibitors are used in the treatment of DM?

A

Incretins – DPP-4 anatagonists: Sitagliptin, saxaglipitin, linagliptin, vildaglipitin – the “liptins

36
Q

Linaliptin
MOA
T1DM or T2DM?

A

Incretins – DPP-4 anatagonists: Sitagliptin, saxaglipitin, linagliptin, vildaglipitin – the “liptins”

***These drugs will only be useful in T2DM***

MOA:
GLP-1 is secreted by the L-cells in the distal ileum and colon and increases glucose dependent insulin secretion, decreases glucagon release, decreases gastric emptying, and increases satiety – all of these actions decrease postprandial glucose – THIS DRUG ACTS TO BLOCK DIPEPTIDYL PEPTIDASE-4 (DPP-4) that BREAKS DOWN GLP-1.

37
Q

Linagliptin
Side Effects

A

Incretins – DPP-4 anatagonists: Sitagliptin, saxaglipitin, linagliptin, vildaglipitin – the “liptins”

***These drugs will only be useful in T2DM***

Side Effects:

Mild Urinary or Respiratory infections; weight neutral

38
Q

saxagliptin
MOA
T1DM or T2DM?

A

Incretins – DPP-4 anatagonists: Sitagliptin, saxaglipitin, linagliptin, vildaglipitin – the “liptins”

***These drugs will only be useful in T2DM***

MOA:
GLP-1 is secreted by the L-cells in the distal ileum and colon and increases glucose dependent insulin secretion, decreases glucagon release, decreases gastric emptying, and increases satiety – all of these actions decrease postprandial glucose – THIS DRUG ACTS TO BLOCK DIPEPTIDYL PEPTIDASE-4 (DPP-4) that BREAKS DOWN GLP-1.

39
Q

Saxagliptin
Side Effects

A

Incretins – DPP-4 anatagonists: Sitagliptin, saxaglipitin, linagliptin, vildaglipitin – the “liptins”

***These drugs will only be useful in T2DM***

Side Effects:

Mild Urinary or Respiratory infections; weight neutral

40
Q

sitagliptin
MOA
T1DM or T2DM?

A

Incretins – DPP-4 anatagonists: Sitagliptin, saxaglipitin, linagliptin, vildaglipitin – the “liptins”

***These drugs will only be useful in T2DM***

MOA:
GLP-1 is secreted by the L-cells in the distal ileum and colon and increases glucose dependent insulin secretion, decreases glucagon release, decreases gastric emptying, and increases satiety – all of these actions decrease postprandial glucose – THIS DRUG ACTS TO BLOCK DIPEPTIDYL PEPTIDASE-4 (DPP-4) that BREAKS DOWN GLP-1.

41
Q

Sitagliptin
Side Effects

A

Incretins – DPP-4 anatagonists: Sitagliptin, saxaglipitin, linagliptin, vildaglipitin – the “liptins”

***These drugs will only be useful in T2DM***

Side Effects:

Mild Urinary or Respiratory infections; weight neutral

42
Q

Vildagliptin
MOA
T1DM or T2DM?

A

Incretins – DPP-4 anatagonists: Sitagliptin, saxaglipitin, linagliptin, vildaglipitin – the “liptins”

***These drugs will only be useful in T2DM***

MOA:
GLP-1 is secreted by the L-cells in the distal ileum and colon and increases glucose dependent insulin secretion, decreases glucagon release, decreases gastric emptying, and increases satiety – all of these actions decrease postprandial glucose – THIS DRUG ACTS TO BLOCK DIPEPTIDYL PEPTIDASE-4 (DPP-4) that BREAKS DOWN GLP-1.

43
Q

Vildagliptin
Side Effects

A

Incretins – DPP-4 anatagonists: Sitagliptin, saxaglipitin, linagliptin, vildaglipitin – the “liptins”

***These drugs will only be useful in T2DM***

Side Effects:

Mild Urinary or Respiratory infections; weight neutral

44
Q

What Amylin analogs are used in the treatment of DM?
T1DM or T2DM?

A
  • *Amylin Analogues** - Pramlinitide
  • *T1 AND T2 DM**.
45
Q

Pramlinitide
MOA

A

Amylin Analogues - Pramlinitide

MOA:
Amylin is a physiological compound released from the ß-cells in the pancreas. It Lowers glucagon, decreases gastric emptying, and acts on HYPOTHALMUS to promote satiety (satiety is important in preventing people from eating more and causing an even greater rise in post-prandial glucose)

46
Q

Pramlinitide
Side Effects
Administration

A

Amylin Analogues - Pramlinitide

Side Effects:
Hypoglycemia

Administration:

SC

47
Q

What bile-acid sequestrants are used in the treatment of DM?

A

Bile-acid sequestrants – Colesevelam hydrochloride

48
Q

Diazoxide
MOA
Indication

A

Diazoxide
MOA:
Anti-hypertensive diuretic that has potent hyperglycemic action by preventing insulin secretion (not synthesis)

Indication:
Used to treat inoperable insulinomas

49
Q

Octreotide
MOA
Indication

A

Octreotide
MOA:
Somatostatin analog – remember somatostatin decreases release of GH, TSH, insulin, and glucagon

Indication:
Tumors that cause increased release of GH, TSH, insulin, or glucagon

50
Q

What two drugs are used in the treatment of insulin secreting tumors?

A

Octreotide
MOA:
Somatostatin analog – remember somatostatin decreases release of GH, TSH, insulin, and glucagon

Indication:
Tumors that cause increased release of GH, TSH, insulin, or glucagon

51
Q

What SGLT2 inhibitors are used in the treatment of DM?
T1DM or T2DM?

A

SGLT2 Inhibitors: Cingaflozin, Dapagliflozin, Empagliflozin - the “flozins”

T2DM only

52
Q

Canaglifozin
MOA

A

SGLT2 Inhibitors: Cingaflozin, Dapagliflozin, Empagliflozin

MOA:
Sodium Dependent Glucose Transporters that normally cause 100% glucose reabsorption in the PROXIMAL CONVOLUTED TUBULES of the kidney are inhibited. This leads to more glucose in the urine (it does not stimulate secretion of glucose in the kidney – this never happens)

53
Q

Canaglifozin
Side Effects
Contraindications

A

SGLT2 Inhibitors: Cingaflozin, Dapagliflozin, Empagliflozin

Side Effects:

INCREASED SERUM KETONE BODIES – LESS GLYCOLYSIS, MORE LIPOLYSIS
GLUCOSURIA -> MORE UTIS, YEAST INFECTIONS, HYPERKALEMIA, AND DEHYDRATION

Containdications:
severe renal impairment, end stage renal disease, patients on dialysis

54
Q

Dapagliflozin
MOA

A

SGLT2 Inhibitors: Cingaflozin, Dapagliflozin, Empagliflozin

MOA:
Sodium Dependent Glucose Transporters that normally cause 100% glucose reabsorption in the PROXIMAL CONVOLUTED TUBULES of the kidney are inhibited. This leads to more glucose in the urine (it does not stimulate secretion of glucose in the kidney – this never happens)

55
Q

Dapagliflozin
Side Effects
​Contraindications

A

SGLT2 Inhibitors: Cingaflozin, Dapagliflozin, Empagliflozin

Side Effects:

INCREASED SERUM KETONE BODIES – LESS GLYCOLYSIS, MORE LIPOLYSIS
GLUCOSURIA -> MORE UTIS, YEAST INFECTIONS, HYPERKALEMIA, AND DEHYDRATION

Containdications:
severe renal impairment, end stage renal disease, patients on dialysis

56
Q

Empaglifozin
MOA

A

SGLT2 Inhibitors: Cingaflozin, Dapagliflozin, Empagliflozin

MOA:
Sodium Dependent Glucose Transporters that normally cause 100% glucose reabsorption in the PROXIMAL CONVOLUTED TUBULES of the kidney are inhibited. This leads to more glucose in the urine (it does not stimulate secretion of glucose in the kidney – this never happens)

57
Q

Empagliflozin
Side Effects
​Contraindications

A

SGLT2 Inhibitors: Cingaflozin, Dapagliflozin, Empagliflozin

Side Effects:

INCREASED SERUM KETONE BODIES – LESS GLYCOLYSIS, MORE LIPOLYSIS
GLUCOSURIA -> MORE UTIS, YEAST INFECTIONS, HYPERKALEMIA, AND DEHYDRATION

Containdications:
severe renal impairment, end stage renal disease, patients on dialysis

58
Q
A

PharmB (29 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions